523 related articles for article (PubMed ID: 16997053)
1. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
[TBL] [Abstract][Full Text] [Related]
2. [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].
Busch M; Franke S; Stein G; Wolf G;
Dtsch Med Wochenschr; 2007 Sep; 132(36):1810-4. PubMed ID: 17726651
[TBL] [Abstract][Full Text] [Related]
3. Serum carboxymethyllysine predicts mortality in hemodialysis patients.
Wagner Z; Molnár M; Molnár GA; Tamaskó M; Laczy B; Wagner L; Csiky B; Heidland A; Nagy J; Wittmann I
Am J Kidney Dis; 2006 Feb; 47(2):294-300. PubMed ID: 16431258
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic value of advanced glycation end-products in chronic heart failure.
Hartog JW; Voors AA; Schalkwijk CG; Scheijen J; Smilde TD; Damman K; Bakker SJ; Smit AJ; van Veldhuisen DJ
Eur Heart J; 2007 Dec; 28(23):2879-85. PubMed ID: 17986469
[TBL] [Abstract][Full Text] [Related]
7. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
[TBL] [Abstract][Full Text] [Related]
8. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
9. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
[TBL] [Abstract][Full Text] [Related]
10. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study.
Kilhovd BK; Juutilainen A; Lehto S; Rönnemaa T; Torjesen PA; Birkeland KI; Berg TJ; Hanssen KF; Laakso M
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):815-20. PubMed ID: 15692098
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of advanced glycation end products in children with renal disease.
Sebeková K; Podracká L; Blazícek P; Syrová D; Heidland A; Schinzel R
Pediatr Nephrol; 2001 Dec; 16(12):1105-12. PubMed ID: 11793110
[TBL] [Abstract][Full Text] [Related]
12. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy.
Lo MK; Lee KF; Chan NN; Leung WY; Ko GT; Chan WB; So WY; Ng MC; Ho CS; Tam JS; Lam CW; Tong PC; Chan JC
Diabetes Obes Metab; 2004 May; 6(3):223-30. PubMed ID: 15056131
[TBL] [Abstract][Full Text] [Related]
13. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.
Zoppini G; Targher G; Chonchol M; Perrone F; Lippi G; Muggeo M
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):580-6. PubMed ID: 19196499
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.
Endo M; Yanagisawa K; Tsuchida K; Okamoto T; Matsushita T; Higuchi M; Matsuda A; Takeuchi M; Makita Z; Koike T
Horm Metab Res; 2001 May; 33(5):317-22. PubMed ID: 11440280
[TBL] [Abstract][Full Text] [Related]
15. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
Jafar TH; Schmid CH; Stark PC; Toto R; Remuzzi G; Ruggenenti P; Marcantoni C; Becker G; Shahinfar S; De Jong PE; De Zeeuw D; Kamper AL; Strangaard S; Levey AS
Nephrol Dial Transplant; 2003 Oct; 18(10):2047-53. PubMed ID: 13679479
[TBL] [Abstract][Full Text] [Related]
16. A novel advanced glycation index and its association with diabetes and microangiopathy.
Sampathkumar R; Balasubramanyam M; Rema M; Premanand C; Mohan V
Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
[TBL] [Abstract][Full Text] [Related]
17. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein.
Busch M; Franke S; Müller A; Wolf M; Gerth J; Ott U; Niwa T; Stein G
Kidney Int; 2004 Jul; 66(1):338-47. PubMed ID: 15200442
[TBL] [Abstract][Full Text] [Related]
18. Severity of diabetic microvascular complications is associated with a low soluble RAGE level.
Grossin N; Wautier MP; Meas T; Guillausseau PJ; Massin P; Wautier JL
Diabetes Metab; 2008 Sep; 34(4 Pt 1):392-5. PubMed ID: 18701333
[TBL] [Abstract][Full Text] [Related]
19. Concomitant macro and microvascular complications in diabetic nephropathy.
Alwakeel JS; Al-Suwaida A; Isnani AC; Al-Harbi A; Alam A
Saudi J Kidney Dis Transpl; 2009 May; 20(3):402-9. PubMed ID: 19414942
[TBL] [Abstract][Full Text] [Related]
20. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy.
Ogawa Y; Goto T; Tamasawa N; Matsui J; Tando Y; Sugimoto K; Tomotsune K; Kimura M; Yasujima M; Suda T
Diabetes Res Clin Pract; 2008 Feb; 79(2):357-61. PubMed ID: 17980929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
